Sign up to save your podcasts
Or
Share ICIs In Esophageal & GEJ Cancers
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
ICIs In Esophageal & GEJ Cancers
Updates on the use of immune-checkpoint inhibitors in esophageal and gastro-esophageal junction (GEJ) cancers.
First, adjuvant nivolumab (Checkmate 577). Then, pembrolizumab + chemo for initial treatment of metastatic disease (Keynote 590). Also, we mention 2 new approvals for myeloma: the 1st CAR-T for the disease and an expanded indication for isatuximab.
View all episodes
By John Bossaer
4.9
185185 ratings
Updates on the use of immune-checkpoint inhibitors in esophageal and gastro-esophageal junction (GEJ) cancers.
First, adjuvant nivolumab (Checkmate 577). Then, pembrolizumab + chemo for initial treatment of metastatic disease (Keynote 590). Also, we mention 2 new approvals for myeloma: the 1st CAR-T for the disease and an expanded indication for isatuximab.
More shows like OncoPharm
View all
JAMA Clinical Reviews
499 Listeners
The Daily
112,858 Listeners
Up First from NPR
56,917 Listeners
Armchair Expert with Dax Shepard
69,546 Listeners
ASCO Guidelines
45 Listeners
The Peter Attia Drive
8,631 Listeners
OncLive® On Air
22 Listeners
Raising Good Humans
1,893 Listeners
Oncology Today with Dr Neil Love
57 Listeners
Huberman Lab
29,275 Listeners
The Money with Katie Show
1,559 Listeners
Two Onc Docs
191 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
45 Listeners
WolverHeme Happy Hour
30 Listeners
Good Hang with Amy Poehler
12,391 Listeners